主持科研及人才项目

1.江苏省人力资源和社会保障厅，2022ZB799，LCN2调控JAK/STAT3信号通路在紫绀型先心病慢性缺氧致神经发育障碍中的作用及机制研究，2022.6-2024.6，30万元

2.国家自然科学基金面上项，82270310，Atoh1转录调控Kif21b：紫绀型先心病慢性缺氧致神经发育障碍中的干预新靶点，2023.1-2026.12，51万元，主要参与者

代表性论文

1. Patel N, Xu W, Deng Y, Jin J, Zhang H. Cross-Scale Integration of Nano-Sized Extracellular Vesicle-Based Biomarker and Radiomics Features for Predicting Suspected Sub-Solid Pulmonary Nodules. Journal of Biomedical Nanotechnology, 2021, 17(6): 1109-1122.

2. Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Management and Research, 2017, 9: 243-248.

3. Patel N, Xiong J, Ding S, Zhang H. Pigment epithelium derived factor as a novel tumorigenic factor for esophageal cancer. Oncology Letters, 2017, Accepted article (ID:173801).

4. Xu W, Patel N, Deng Y, Ding S, Zhang H. Extracellular vesicle-derived LINC00482 induces microglial M2 polarization to facilitate brain metastasis of NSCLC. Cancer Letters. 2023, 561: 216146.

5. Yan L, Patel N, Zhang H. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Review of Gastroenterology and Hepatology. 2019, 13(12): 1169-1180.

6. Ding S, Patel N, Zhang H. Ciclosporin A as a Reversal Agent Against Concurrent Multidrug Resistance in Tumors with Nanobubbles. Journal of Biomedical Nanotechnology, 2018, 14(1): 190-197 7.

7. Zhang H, Patel N, Ding S, Xiong J, Wu P. Theranostics for hepatocellular carcinoma with Fe3O4@ZnO nanocomposites. Biomaterials Science, 2016, 4(2): 288-298.

8. Zhang H, Patel N, Xiong J, Ding S. Targeting and noninvasive treatment of hepatocellular carcinoma in situ by ZnO nanorod mediated concurrent chemoradiotherapy. RSC Advances. 2015, 5: 85720.

9. Wu P, Li S, Zhang H. Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes. Drug Design, Development and Therapy. 2014, 8: 2431-2438.

10. Deng Y, Xue R, Patel N, Xu W, Zhang H. Serum Extracellular Nano-Vesicles miR-153-3p to Identify Micronodular Lung Cancer from Sub-Centimeter Lung Nodules. Journal of Biomedical Nanotechnology. 2022, 18(3): 705-717.

11. Deng Y, Qiu T, Patel N, Zhou S, Xue T, Zhang H. Clinical management of risk of radiation pneumonia with serum markers during the radiotherapy for patients with thoracic malignant tumors. Cancer Management and Research. 2019, 11: 10249-10256.

12. Zhang H, Xiong J, Guo L, Patel N, Guang X. Integrated traditional Chinese and western medicine modulator for overcoming the multidrug resistance with carbon nanotubes, RSC Advances. 2015, 5: 71287.

13. Song P, Ma S, Deqin Z, Wu K, Patel N, An J, Yang Z, Mo X. Bioinformatic analysis identifies GPR91 as a potential key gene in brain injury after deep hypothermic low flow. Heliyon. 2023, 9(5): e15286.

14. Song P, Ma S, Deqin Z, Wu K, Yang Z, Patel N, Liu X, Mo X. The potential value of cuprotosis in myocardial immune infiltration that occurs in pediatric congenital heart disease in response to surgery with cardiopulmonary bypass. Immunity, Inflammation and Disease. 2023, 11(3); e795.

15. Patel N, Dong D, Ding P, Wu K, Yang Z, Mo X. Clinical trends of children with primary cardiac tumors: 15-year experience from a single center. Journal of Clinical Oncology. 2023, 41(16_suppl): e22008.

16. Patel N, Jin J, Zhang H. P62.04. Neoteric small extracellular vesicles based biomarker for predicting cancerous sub-solid nodules of lung. Journal of Thoracic Oncology. 2021, 16(10), S1178.

17. Patel N, Ren L, Zhang H. PS16.11 Novel serum exosomal miRNAs blend into radiogenomics to predict Early-stage Lung cancer at foremost biopsy. Journal of Extracellular Vesicles. 2021, 10: e12083.

18. Patel N, Zhang H, Ren L. Abstract 58: Serum based exosomal miRNAs as in novel biomarkers for the initial prediction of early-stage lung cancer. Cancer Epidemiology Biomarkers and Prevention. 2021, 30: 58.

19. Zhang H, Patel N, Wu P. A comparison of gefitinib for advanced non-small cell lung cancer patients with different EGFR mutation types. Journal of Clinical Oncology, 2017, 35(15_suppl): e20544.

授权专利

1.发明专利：种跨尺度整合评估肺结节恶性风险预测系统，202111006498.9，申请日：2021-08-30，发明人：张海军、李尚沙马尔拜帕特尔、靳激扬

获奖

1.江苏省人力资源和社会保障厅，省级，省卓越博士后，2022.11

2.中国政府优秀来华留学生奖学金，国家级，东南大学海外学院，2019-2020年度

3.南京政府外国留学生奖学金，市级，东南大学海外学院，2014～2021年（每年）

4.东南大学留学生奖学金，校级，东南大学海外学院，2014～2021年（每年）